Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

NCT04412668
View directory record Official record
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Not applicable Interventional

Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID

NCT06883513
View directory record Official record
Conditions
Long-COVID, PASC, Long COVID Syndrome
Interventions
Osteopathic Manipulative Therapy Long-COVID protocol, Osteopathic Manipulative Therapy NOT Long-COVID treatment protocol
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 13, 2026, 10:22 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of COVID-19 Antibodies Kingman AZ

NCT04533360
View directory record Official record
Conditions
Covid19
Interventions
VITROS Anti-SARS-CoV-2 IgG test
Diagnostic Test
Lead sponsor
Kingman Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kingman, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

NCT04557046
View directory record Official record
Conditions
Covid19
Interventions
Nasal Swab, Nasopharyngeal swab, Throat swab, Fingerstick, Saliva specimen
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Altamonte Springs, Florida • Kissimmee, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388
View directory record Official record
Conditions
SARS-CoV-2
Interventions
REGN14256, imdevimab, casirivimab + imdevimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

NCT05890586
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780424
View directory record Official record
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

NCT06207929
View directory record Official record
Conditions
Influenza, Human, COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions
Not listed
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
18,157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)

NCT04595175
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Not listed
Lead sponsor
Brian Tiffany, MD
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 13, 2026, 10:22 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

NCT07703475
View directory record Official record
Conditions
COVID -19
Interventions
RVX-sCPD9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
View directory record Official record
Conditions
Covid-19
Interventions
CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Chula Vista, California • El Centro, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Long-Covid-19 Alleviation Through Learning Mindfulness Study

NCT07140094
View directory record Official record
Conditions
Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, COVID Long-Haul
Interventions
Structured mindfulness intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

NCT04365153
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational

SARS-CoV-2 IgG and IgM Serologic Assays

NCT04562246
View directory record Official record
Conditions
Covid19
Interventions
Serologic assays for antibodies to SARS-CoV-2
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Merging Yoga and Self-Management Skills for Symptoms of Long COVID

NCT05697042
View directory record Official record
Conditions
Long COVID
Interventions
MY-Skills for Long COVID
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational

Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program

NCT04443803
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Randy Loftus
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 13, 2026, 10:22 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Changes in Cellular Immune Profile During COVID-19 Infection

NCT04470999
View directory record Official record
Conditions
Covid19, SARS-CoV-2
Interventions
Leukapheresis
Other
Lead sponsor
Serhat Gumrukcu, MD PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298
View directory record Official record
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational

Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass

NCT05357885
View directory record Official record
Conditions
Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass
Interventions
SARS-CoV-2 Antibody test
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind

NCT05367908
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 13, 2026, 10:22 PM EDT